Research

Johnson & Johnson Extends Collaboration With Rigel

Published in Cancer Weekly, January 29th, 2002

Rigel Pharmaceuticals, Inc., (RIGL) has announced that its oncology drug discovery collaboration with Johnson & Johnson Pharmaceutical Research & Development has been extended for another two years.

Under the terms of the extension agreement, Rigel will continue to validate targets discovered during the collaboration. Johnson & Johnson Pharmaceutical Research & Development will conduct high-throughput screening and medicinal chemistry to identify small-molecule drugs that modulate validated targets selected for drug discovery.

"Rigel's drug discovery and target validation engine is successfully identifying targets for small-molecule screening at...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry